intetumumab (CNTO 95) / J&J - LARVOL DELTA

Anti-interleukin-23 agents for the treatment of ulcerative colitis. (PubMed, Expert Opin Biol Ther) - "The interleukin (IL)-23 axis plays a significant role in the pathogenesis of UC and has thus become an important target for drug development.Areas coveredThe review briefly summarizes the pathophysiology of the IL-12/23 axis and provides a synopsis of the available evidence for efficacy and safety of ustekinumab, mirikizumab (LY3074828), risankizumab (BI655066/ABBV066), brazikumab (MEDI2070; formerly AMG139) and guselkumab (CNTO1959) in UC. Trials of other anti-IL-23 agents in UC are under way and designed to explore head-to-head efficacy with existing biologics, as well as the prospect of combination biological therapy. Apart from data on longer term efficacy and safety, future trials should also explore strategies to inform the positioning of IL-23 antagonists in therapeutic algorithms."

Journal • IL12A

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Janssen Pharmaceutical K.K.; Recruiting ➔ Completed

Clinical • Trial completion